Since the sell off on Feb. 6 this stock is extremely undervalued. A positive PR next week will propel the share price up to the $3.75 level of a year ago at this time.
A-7 is reaching a durable ORR of 20% or more in it's treatment arm vs. the durable ORR of 4% for DTIC.
ORR will not matter - might get approval from FDA (based on SPA) but for marketing purposes OS is the most important thing. A-7 need to demonstrate that the OS derived is much better than current SOC(i, e Yervoy). If A-7 can show a MOS of 16/25 - That would be a home run.
Agreed. Undervalued. Look at FDA's approval of Kadcyla today. Approx. 10 more month's of life for a insured patient's cost of Approx. $ 94,000. Without tried to calculate A-7's patient survival time we are looking pretty good in my unsolicited opinion. I think going into this years annual shareholder meeting we could have multiple events to cheer for.